ATAI
phase study design prospective randomized double blind placebo controlled study of single and multiple ascending doses of part single ascending dose part multiple ascending dose treatment safety treatment safety up to healthy subjects up to cohorts to up to healthy subjects up to cohorts to every hours for days adverse events were mild in most cases with no severe or serious adverse events or dose relation with minimal sedation or dizziness administered evaluate tolerability | ATAI
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
29 of 41
Related slides by other companies
MAIA Biotechnology
Investor Presentation
November 2023
thio trial planned a | MAIA Biotechnology
Ocuphire Pharma
Results
March 2021
secondary safety findings | Ocuphire Pharma
BioAtla
Investor Presentation
August 2022
phase study design with | BioAtla
BioAtla
Investor Presentation
August 2022
phase study design with in refractory patients | BioAtla
Other recent decks by ATAI
See all presentations (13 decks)
Investor Presentation
January 2024
Investor Presentation
October 2023
Investor Conference
May 2023
Investor Presentation
April 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io